TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.
China208 participantsStarted 2025-10-01
Plain-language summary
The investigators assessed the effect of TNF-α antagonism within 6 hours of return of spontaneous circulation on 30-day mortality in patients who remained comatose after cardiopulmonary resuscitation (CPR) following cardiac arrest . In addition, the investigators explored the role of this treatment in modulating the systemic inflammatory response and its potential impact on 90- and 180-day morbidity and mortality and neurological outcomes.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Patients aged ≥18 years;
. Patients with suspected cardiogenic cardiac arrest;
. Patients with comatose state after ROSC (Glasgow Coma Scale \[GCS\] score \<9);
. Patients with Return of spontaneous circulation (ROSC) sustained for \>20 minutes;
Exclusion criteria
. Cardiac arrest due to trauma;
. Suspected or confirmed hemorrhagic or ischemic stroke;
. Pregnancy;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial is looking at TNF-α antagonists to reduce inflammation after cardiac arrest — can you explain what TNF-α antagonists are and whether this type of treatment would make sense given my specific situation after cardiac arrest?
2Since the trial is listed as 'active, not recruiting,' does that mean there's no chance of me joining it, and if so, are there any similar studies or treatments targeting post-cardiac arrest inflammation that I might still be eligible for?
3The trial's main goal is measuring 30-day survival rate — what does that tell us about where researchers are in understanding whether this treatment actually works, and how does that uncertainty compare to standard care I might receive right now?
4Post cardiac arrest syndrome can involve many complications — can you help me understand whether the inflammatory response being targeted in this trial is something that's a concern in my case, and how that might affect my treatment plan?
5Are there any approved or standard treatments that already address the systemic inflammatory response after cardiac arrest that I should consider alongside or instead of an experimental approach like this one?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
. Persistent cardiogenic shock (defined as systolic blood pressure below 90mmHg during the screening period despite adequate fluid resuscitation, vasopressors, and positive inotropic drug support);
. Time from ROSC to randomization exceeding 4 hours;
. Left ventricular ejection fraction (LVEF) \<35% after ROSC;